Abstract
Respiratory syncytial virus (RSV) is a leading cause of Acute Respiratory Tract Infections (ARTIs) in young children. However, there is currently no vaccine or treatment available for children. Here, we demonstrated that nasal-spraying probiotics containing 5 billion of Bacillus spores (LiveSpo Navax) is an effective symptomatic treatment in a 6-day randomized controlled clinical study for RSV-infected children (n = 40-46/group). Navax treatment resulted in 1-day faster recovery-time and 10-50% better efficacy in relieving ARTI symptoms. At day 3, RSV load and level of pro-inflammatory cytokines in nasopharyngeal samples was reduced by 630 folds and 2.7-12.7 folds respectively. This showed 53-fold and 1.8-3.6-fold more effective than those in the control-standard of care-group. In summary, nasal-spraying Bacillus spores can rapidly and effectively relieve symptoms of RSV-induced ARTIs while exhibit strong impacts in reducing viral load and inflammation. Our nasal-spraying probiotics may provide a basis for simple-to-use, low-cost, and effective treatment against viral infection in general.
【초록키워드】 Treatment, Inflammation, viral infection, Efficacy, Vaccine, children, Symptom, virus, Symptoms, Randomized, Viral load, RSV, Impact, Symptomatic treatment, respiratory, clinical study, pro-inflammatory cytokine, spore, Bacillus, nasopharyngeal sample, effective, tract, faster, reducing, demonstrated, was reduced, 【제목키워드】 children, Infection, respiratory syncytial virus, Symptomatic treatment, spore, Bacillus, effective,